Digital Biotechnologies, a subsidiary of Adaptive Biotechnologies Corporation, has completed the initial closing of its Series A preferred stock financing, expected to raise up to $15 million in total proceeds. The round closed on 30 December 2025. Adaptive Biotechnologies currently owns 70% of Digital Biotechnologies. Following the Series A financing, Adaptive expects to retain nearly 50% ownership of the subsidiary and will continue consolidating Digital Biotechnologies' financial results in its statements.

Adaptive Biotechnologies to present at the 44th Annual J.P. Morgan Healthcare Conference. SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies' management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.adaptivebiotech.com. About Adaptive Biotechnologies Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptivebiotech believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptivebiotech apply its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Its commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Its goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 [email protected] ADAPTIVE MEDIA Erica Jones, Associate Corporate Communications Director 206-279-2423 [email protected]

Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B. Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year's end, tapping Harbour BioMed for a multiyear research deal. The new pact will see the companies team up to "advance and accelerate multi-specific antibody discovery programs," according to a Dec. 17 release. In exchange for this work, Harbour will be eligible to receive $90 million. For candidates that progress further down the line, development and commercial milestones worth up to $1.035 billion are on the table, according to the release. "This collaboration leverages our Harbour Mice fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential," Jingsong Wang, M.D., Ph.D., founder, chairman and CEO of Harbour, said in the release. A key element to the deal also sees BMS able to tap into Harbour's "established development capabilities," namely by conducting early clinical trials in China, where Shanghai-based Harbour has an established research presence. "By uniting the strengths of our platform with Bristol Myers Squibb's expertise in drug discovery and development, we look forward to progressing these programs and delivering transformative therapies to patients worldwide," Wang added. This builds on several deals for Harbour with pharmas this year, including Otsuka Pharmaceutical paying out $47 million upfront for the ex-China rights to Harbour's early-stage BCMAxCD3 bispecific candidate back in June. That deal came with $623 million biobucks attached, plus potential royalties on future net sales. But by far its biggest was the potential $4.4 billion biobucks deal with AstraZeneca that also used its Harbour Mice platform. BMS has also put several billion dollars on the table with its deals this year, including its massive bispecific tie-up with BioNTech in June and its $1.5 billion buyout of Orbital Therapeutics in October. And as we reach the end of 2025, several Big Pharmas have found some spare cash ahead of the New Year for a host of deals over the past few weeks. Most recently this saw Roche's Genentech unit pen a pact with Caris Life Sciences offering up to $1.1 billion in possible R&D, commercial and sales milestones, plus potential royalties for new cancer targets. Earlier this week, Sanofi also teamed up with two separate biotechs, while Pfizer too signed a new deal with Adaptive Biotechnologies.